US EditionPublished • loading... • Updated
GSK's Chronic Hepatitis B Therapy Shows Promise in Key ...
Bepirovirsen showed significantly higher functional cure rates in global Phase 3 trials with 1,800 patients, offering a potential six-month finite therapy for chronic hepatitis B.
- On January 7, 2026, GSK announced positive Phase 3 results from B-Well 1 and B-Well 2 trials, which met their primary endpoint showing a significant functional cure rate for bepirovirsen.
- CHB remains a major global health challenge, affecting more than 250 million people worldwide and linked to around 1.1 million deaths annually; achieving a functional cure is critical.
- The Phase 3 trials enrolled over 1,800 patients across 29 countries, with bepirovirsen given as a weekly subcutaneous injection over a six-month course, achieving higher cure rates and good safety.
- If approved, bepirovirsen could become the first finite six-month therapy and GSK projects peak sales of around �2 billion, while Ionis could receive $150 million in milestone payments and 10-12% royalties.
- Detailed trial data remain unpublished, and full clinical results will be presented at a scientific congress and published in a peer-reviewed journal; GSK is also following patients in the B-Sure long-term extension study that will run for around three years.
Insights by Ground AI
13 Articles
13 Articles
GSK Gets Closer to Bringing Patients a Functional Cure for Chronic Hepatitis B
GSK’s bepirovirsen met the main goal of two Phase 3 studies, achieving functional cure rates for patients with chronic hepatitis B infection after six months of treatment. This antisense oligonucleotide therapy could provide a treatment alternative to antiviral drugs that patients must take for life. The post GSK Gets Closer to Bringing Patients a Functional Cure for Chronic Hepatitis B appeared first on MedCity News.
Coverage Details
Total News Sources13
Leaning Left1Leaning Right0Center6Last UpdatedBias Distribution86% Center
Bias Distribution
- 86% of the sources are Center
86% Center
14%
C 86%
Factuality
To view factuality data please Upgrade to Premium